Navigation Links
Discovery suggests new combination therapy strategy for basal-like breast cancers
Date:5/21/2012

CHAPEL HILL, N.C. Multiple research projects including a 2006 study conducted at the University of North Carolina at Chapel Hill have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.

A new study led by UNC Lineberger scientist Charles Perou, PhD, and Sean Egan, PhD, from The Hospital for Sick Children in Toronto, Ontario, demonstrates that deletion of a sugar transferase called LFNG (nicknamed "lunatic fringe"), promotes cell proliferation and tumor formation of basal-like breast cancers. The study was published last week in the journal Cancer Cell.

In a laboratory model, the deletion of LFNG not only caused tumors to form but also activated two cellular signaling pathways thought to be important in tumor formation. The team found increased activation of both notch signaling (a receptor found on the surface of cells that is involved in stem cell differentiation and development) and increased expression of the Met oncogene.

Taking the laboratory model a step further, the team examined these same genes and signaling pathways in basal-like tumors and found the same genetic signature.

"This is exciting because there are drugs in development that target each of these pathways. While targeting each pathway alone might work, our findings suggest that combination therapy could be a promising strategy for treating these basal-like tumors," says Dr. Perou, who is the May Goldman Shaw Distinguished Professor of Molecular Oncology and professor of genetics, and pathology and laboratory medicine at the UNC School of Medicine.

Basal-like breast cancer tends to be more aggressive and have a poorer prognosis than other types, making up about 15 percent of all breast cancers. In young African-American women who develop breast cancer, the subtype makes up about 39 percent of all diagnoses. It is primarily treated with chemotherapy, although newer targeted drugs are being tested in clinical trials.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina Health Care
Source:Eurekalert

Related medicine news :

1. Researchers make promising discovery in pursuit of effective lymphoma treatments
2. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
3. H1N1 discovery paves way for universal flu vaccine: UBC research
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. Discovery could help to develop drugs for organ transplant and cancer patients
6. Washingtons Life Sciences Discovery Fund awards commercialization grants
7. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
8. New discovery of proteins involved in positioning muscular nuclei
9. Cell signaling discovery provides new hope for blood disorders
10. Gene mutation discovery sparks hope for effective endometriosis screening
11. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2019)... ... , ... Cocoa Beach is preparing to host its 10th annual “Surfing Santas” ... , What began as a simple family beach day a decade ago has grown ... years in, there’s no better place for Santa to loosen up as he gets ...
(Date:12/6/2019)... , ... December 06, 2019 , ... ... has been recognized for excellence in employee learning. The Omaha-based company has been ... organizations with the most successful employer-sponsored training and development programs worldwide. Rankings of ...
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... Lasair Aesthetic Health Sponsors Toys for Tots ... Units of Botox to Patients Who Bring in Toys During the Holidays , Lasair Aesthetic ... From now until Christmas, patients who bring in a toy or toys worth more than ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... resolution ultrasound (HRUS) technology to help their patients more easily detect ruptured silicone ... participating in this study and reporting on his experience. While the FDA currently ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... patients met the hospital's newest staff member who will to help them take ... and affection during medical procedures.  , Rocket, presented by NutriSource® is a golden ...
Breaking Medicine News(10 mins):
(Date:12/5/2019)... ... December 05, 2019 , ... ... and dialogue, today announces key issues to be discussed at its East/West ... Seasons Hotel in San Francisco. , Kicking off the week ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex Health, Inc., a ... to treat chronic pain in soft and hard tissue, recently achieved a major ... , Dr. Bernard Morrey, Chief Medical Officer of Tenex Health, said, “Our ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... announced the Top 17 Master's in Organizational Psychology Degree Programs for 2020. The ... universities in the nation. Each program is evaluated based on curriculum quality, graduation ...
Breaking Medicine Technology: